← Glossary

Breakthrough Therapy Designation

BTD

FDA & Regulatory

Breakthrough Therapy Designation (BTD) is an FDA program for drugs treating serious conditions where early evidence shows substantial improvement over existing options. It grants intensive FDA guidance and eligibility for faster review pathways.

Related terms

Fast TrackPriority ReviewAccelerated ApprovalOrphan Drug Designation

Learn more

FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors

Track Breakthrough Therapy Designation across 1,000+ biotechs

BioSniper monitors FDA decisions, clinical trials, and catalysts in real time — with evidence-backed AI analysis.

Start Free